Emerging Trends in Multidisciplinary Research (ICETMR-2020) 15-16 May 2020 at Dhonburi Rajabhat University, Bangkok, Thailand (07-Feb-2020)        |

Journal :   Research Journal of Pharmacy and Technology

Volume No. :   13

Issue No. :  2

Year :  2020

Pages :   578-582

ISSN Print :  0974-3618

ISSN Online :  0974-360X


Allready Registrered
Click to Login

Evaluation of In-vitro Antioxidant Activity of Camalexin- A Novel Anti-Parkinson’s agent

Address:   Manasa K*, Chitra V
Department of Pharmacology, SRM College of Pharmacy, SRMIST, Kattankulathur-603203,Tamilnadu, India.
*Corresponding Author
DOI No: 10.5958/0974-360X.2020.00109.2

In the physiological and biochemical, physiological processes of the living system the free radicals (or reactive oxygen species - ROS) are generated. These ROS/ free radicals are scavenged by certain chemical substances called antioxidants and thus help to treat as well as prevent the occurrence of several diseases. Several medicinal plants and their active constituents have the property to protect the antioxidant enzyme systems when treated to the living systems. In the present study, one such isolated compound, camalexin was selected and being studies to evaluate its neuroprotective role in Parkinson’s disease. Initially, the binding capacity of camalexin was evaluated using Autodock 4.2 and reported. In this study, the antioxidant activity of camalexin was evaluated in vitro using ABTS assay, DPPH assay, FRAP assay, hydrogen peroxide assay, nitric oxide assay and super oxide dismutase free radical scavenging methods. Camalexin in various concentrations like 50 µg/ml, 100 µg/ml, 250 µg/ml, 500 µg/ml and 1000 µg/ml were taken and each of the samples were analysed for their antioxidant status by finding its IC50 value. This study suggests that camalexin expressed good antioxidant potential that forms basic evidence in neuroprotection.
Parkinson’s disease, Aldehyde dehydrogenase, Camalexin, Dopamine, Benomyl, Pesticide.
Manasa K, Chitra V. Evaluation of In-vitro Antioxidant Activity of Camalexin- A Novel Anti-Parkinson’s agent. Research J. Pharm. and Tech 2020; 13(2):578-582.
[View HTML]     

Visitor's No. :   743545